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Abstract
Antibiotic multi-resistant pneumonia is a risk associated with long term mechanical ventilation. 
Vancomycin is commonly prescribed for methicillin-resistant staphylococcus aureus infections; 
however, current formulations of vancomycin are only given intravenously. High doses of 
vancomycin have been associated with severe renal toxicity. In this study we characterized dry 
powder vancomyin as a potential inhaled therapeutic aerosol and compared pharmacokinetic 
profiles of i.v. and pulmonary administered vancomycin in intubated rabbits using a novel 
endotracheal tube catheter system. Cascade Impaction studies indicated that using an endotracheal 
tube, which bypasses deposition the mouth and throat, increased the amount of drug entering the 
lung. Drug deposition in the lung was further enhanced by using an endotracheal tube catheter, 
which did not alter the aerosol fine particle fraction. Interestingly, intubated rabbits administered 1 
mg/kg vancomycin via inhalation had similar AUC to rabbits that were administered 1 mg/kg 
vancomycin via a single bolus i.v. infusion; however, inhalation of vancomycin reduced Cmax and 
increased Tmax, suggesting that inhaled vancomycin resulted in more sustained pulmonary levels 
of vancomycin. Collectively, these results suggested that dry powder vancomycin can successfully 
be delivered by pulmonary inhalation in intubated patients. Furthermore, as inhaled vancomycin is 
delivered locally to the site of pulmonary infection, this delivery route could reduce the total dose 
required for therapeutic efficacy and simultaneously reduce the risk of renal toxicity by 
eliminating the high levels of systemic drug exposure required to push the pulmonary dose to 
therapeutic thresholds during i.v. administration.
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Ventilator associated pneumonia (VAP) is a common cause of hospital acquired-
infections1, 2, especially in susceptible populations such as patients with cystic fibrosis and 
in immunocompromised patients.3, 4 Importantly, VAP is associated with increased intensive 
care unit days, associated health care costs, and increased mortality in ventilated patients5, 6, 
with several of these pathogens having multi-drug resistance to antibiotic pharmacotherapy.1 
Vancomycin is the drug of choice for the treatment of bronchopneumonia due to methicillin-
resistant staphylococcus aureus (MRSA)-positive infections,7 but it is only available in oral 
and intravenous formulations; the latter being utilized to treat pneumonia due to the 
extremely poor bioavailability of oral vancomycin.8, 9, 10 Unfortunately, vancomycin is 
associated with renal toxicity and ototoxicity.11 Since i.v. administration of vancomycin runs 
a potential risk for renal toxicity, vancomycin use is generally limited to hospital settings. 
While risk of adverse drug reactions to vancomycin can be minimized with careful 
administration and patient monitoring, novel delivery methods and/or formulations of 
vancomycin that could increase the therapeutic index would be of substantial benefit.
Several experimental ‘off-label’ therapies have aimed at reducing overall systemic drug 
exposure in patients with MRSA-induced pneumonia by delivering vancomycin directly into 
the lungs via inhalation.12, 13 This route of administration delivers a high concentration of 
drug to the lungs, while simultaneously bypassing the high systemic load needed to push 
drug concentrations to therapeutic levels in pulmonary tissues. Currently, this delivery 
method is accomplished by wet nebulization, which forms fine aerosol droplets of drug in-
line with the ventilator for forced ventilator inhalation; however, the only option for 
pulmonary delivery of vancomycin is to administer a nebulized vancomycin that is only 
formulated and approved for IV use. The off-label administration of IV vancomycin has 
proven to be encouraging in clinical settings, although efficacy remains to be determined in 
ventilated patients. The lack of a pulmonary specific vancomycin formulation can increase 
the risk of dosing variability, drug stability, and/or lung irritation; by default, intravenously 
administered vancomycin is remains the standard of care.
Though various kinds of inhalers have been developed for delivering drug aerosols into 
ambulatory patients, only nebulizers and pressurized metered dose inhalers (pMDIs) have 
been routinely used for clinical therapy during mechanical ventilation.14, 15 These devices 
have been fitted to the ventilator circuit by specific in-line adapters. It is well-known that 
pMDI and nebulized formulations suffer from ‘rain-out’, which is the formation of 
condensation of the aerosol drug droplets onto the ventilator circuit and endotracheal 
tubing.16 Drug particles can also get trapped in the existing condensate inside ventilator 
lines and can escape into the exhalation line between breaths resulting in diminished 
pulmonary delivery. Several researchers have attempted to overcome some of these 
pulmonary drug delivery challenges by creating inline adapters that fit dry powder inhaler 
devices (DPI) to deliver a concentrated drug aerosol more accurately.17, 18 An experimental 
dry powder inhaler device was designed and provided the convenience of connecting the 
DPI with the ventilator and endotracheal tubing, while maintaining efficient aerosol delivery 
compared to the direct-to-mouth Monodose® inhaler.18 Unfortunately, fine particle aerosol 
formations are highly sensitive to elevated humidity levels and other variable environmental 
Sullivan et al. Page 2













conditions commonly found in ventilator lines and endotracheal tubes.19 Placing a catheter 
inside of an endotracheal tube integrated into a ventilation line can allow for the delivery of 
a small bolus of non-humidified air containing fine drug powder aerosol for pulmonary 
delivery.20 A fresh catheter could be placed into the endotracheal tube prior to dry powder 
drug delivery and would be minimally affected by humidity within the ventilator line.21 
Combining vancomycin dry powder aerosol with a ventilator endotracheal tube catheter 
could potentially increase the ease, speed, safety, and consistency of vancomycin dosing to 
ventilated patients with MSRA-dependent pneumonia.
In this study, we characterized micronized vancomycin dry powder and identified aerosol 
properties using a Monodose® inhaler coupled to an Anderson Cascade Impactor. We 
further tested the hypothesis that dry powder vancomycin could be delivered through a 
‘catheter’ inserted in a pediatric-sized endotracheal tube and evaluated aerosol performance 
of this system by Anderson Cascade Impaction. Moreover, using this pediatric endotracheal 
set up, we compared pharmacokinetic profiles of rabbits administered inhaled vancomycin 
dry powder or intravenous vancomycin solution.
 Materials and methods
 Materials
Vancomycin hydrochloride (Vanc HCl, Lot No. 14411001) was donated from Savara 
Pharmaceuticals. Vancomycin HCl reference standard powder (RS) and acetonitrile were 
purchased from Sigma Chemicals Co., St Louis, MO. Sodium dihydrogen phosphate, 
phosphoric acid (85%), triethylamine (TEA), tetrahydrofuran (THF) were purchased through 
Fisher Scientific, Fair Lawn, NJ. Double-distilled water used throughout the study was 
provided by an EASYpure® RODI (Model# D13321; Barnstead International), Dubuque, 
IA. A dry powder insufflator was purchased from Penn Century, Inc., Wyndmoor, PA. 
Portex® Un-cuffed oral/nasal pediatric endotracheal tubes (PVC; 2.5 mm I.D. X 3.7 mm 
O.D. X 155 mm length) were purchased from Smiths Medical, Dublin, OH. HPLC tubing 
used for endotracheal catheter (PEEK; 0.6 mm I.D. X 1.2 mm O.D. X 153 mm length) was 
purchased from Cobert Association, St Louis, MO.
 Chemical characterization of vancomycin dry powder
 Purity test—The purity of vancomycin HCL dry powder was determined as defined in 
the U.S. Pharmacopoeia and National Formulary 2011 using HPLC, with slight 
modifications.22, 23 The HPLC system consisted of a Shimadzu CBM-20A system 
controller, LC-10AT solvent delivery pump, SPD-10A UV detector, and SIL-10AxL auto-
injector (Shimadzu Scientific Instrument Inc., Columbia, Maryland). A 4.6 x 250 mm 
Phenomenex C18 Luna (2) column with a particle diameter of 5 μm and a security guard 
Column (Phenomenex C-18 Luna (2) 3.0 x 4.6 mm, 5 μm) were used for separation 
(Phenomenex, Torrance, CA). A gradient elution system was used at a flow rate of 2 mL/min 
with a mobile phase consisting of a mixture of two solutions (Supplementary Table 1). 
Solution A was TEA buffer pH 3.2 (adjusted with phosphoric acid); acetonitrile; and THF 
(93:6:1) and Solution B was composed of TEA buffer pH 3.2; acetonitrile; and THF 
(70:29:1). Detection was performed at 280 nm with an injection volume of 20 μL. 
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Chromatograms were acquired and analyzed using Shimadzu Class vp 7.4 software. The run 
time for the test was 35 minutes, and the retention time for vancomycin B (active component 
of vancomycin) was 9 ± 0.5 min. For the dry powder tested, a sequence of injections was 
performed (Supplementary Table 2). The percentage purity of vancomycin B was calculated 
according to USP as follows22:
Where rB is the area response of the main peak in the chromatogram of Test preparation B; 
and rA is the sum of area response of all peaks except the main peak in the chromatogram of 
Test preparation A.
Where rAi is the area response of any peak except the main peak in the chromatogram of 
Test preparation A.22
 Water content—The water content of the tested powder was determined by Karl Fisher 
(756 KF Coulometer, Metrohm Ion Analysis, Herisau, Switzerland) and were included in the 
potency calculations.
 Potency assay—For the determination of the drug potency and the quantification of 
vancomycin, another analytical method was used as reported by FDA.24 The same HPLC 
system was used as mentioned in the purity test. Here, an isocratic system was used with a 
mobile phase of acetonitrile and 25 mM phosphate buffer pH 3.2 (9:91) at a flow rate of 1 
mL/min and UV detection at 230 nm. The injection volume of the sample was 50 μL. The 
run time for the assay was 30 minutes, and the retention time for vancomycin was 15 ± 0.3 
minutes. The assay was done in triplicate. Vancomycin powder was prepared in a drug 
concentration of 100 μg/mL in 25 mM phosphate buffer pH 3.2 and analyzed for initial drug 
content using a reverse phase HPLC method.25 For RS solution, the peak areas were 
normalized at a concentration of 100 μg/mL and calculated as follows:
Where AN is the normalized peak area, Ari is the peak area in the chromatogram of RS, mri 
is the mass (mg) of RS. The potency of the vancomycin was calculated using the average of 
normalized peak areas of RS at 100 μg/mL as follows:
Where Ai is the peak areas in the chromatogram of the sample to be examined, AN* is the 
average of normalized peak areas of RS at 100 μg/mL and mi is the mass (mg) of the sample 
to be examined.
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 Physical characterization of vancomycin dry powder
 Particle size and morphology by scanning electron microscopy (SEM)—The 
size and morphology of vancomycin dry powder was assessed using a LEO 1550 field 
emission scanning electron microscope (Carl Zeiss NTSC, LLC, Peabody, Maine). Prior to 
imaging, the samples were sputter-coated with gold for 3 min.
 Powder flow characteristics—The bulk and tap densities of vancomycin dry powder 
were estimated by a micro-tap test approach.26, 27 The powder was placed into pre-weighed 
micro-centrifuge tubes, and the tubes were weighed again to determine the mass of powder. 
The tube was then tapped twenty times on the lab bench to compress the powder. The 
volume of the powder was approximated by comparing the height of the compressed powder 
to that of the volume of water in an identical pre-weighed micro-centrifuge tube. The tube 
containing the water was then weighed to determine the volume of water (assuming a 
density of 1 g/cm3). The powder density was calculated by dividing the mass of powder by 
the volume of water.
 Surface area measurement by BET—The surface area of the powder is determined 
by the physical adsorption of a gas (Nitrogen) onto the surface of the sample particles. The 
BET (Brunauer, Emmett and Teller) Theory is commonly used to evaluate the gas adsorption 
data and generate a specific surface area result expressed in units of area per mass of sample 
(m2/g). To perform this test, a known mass of vancomycin dry powder (100 ± 10 mg) was 
placed in a sample tube and the tube was connected to a Surface Area Analyzer (Nova® 
2200e, Quantachrome Instruments). Liquid nitrogen was used to keep the powder samples at 
a low temperature to allow for the formation of a gas monolayer during the measurements, 
leading to an accurate determination of specific surface area. Adsorption data of N2 in the 
relative pressure region from 0.05 to 0.25 was used to fit the BET equation. A BET plot was 
generated, and the slope and y-intercept were used to calculate the specific surface area 
using NovaWin software (version 11.0) that was provided by Quantachrome Instruments.
 Differential scanning calorimetry (DSC)—Vancomycin dry powder was 
investigated by differential scanning calorimetry (DSC, Q100 Universal V4.3A TA 
instruments, New Castle, DE) using 3–5 mg of dry vancomycin powder. Briefly, dry powder 
vancomycin HCl was sealed and placed in a hermetic aluminum pan and heated at a scan 
rate of 10 °C/min over a temperature range of 25–350 °C. An inert atmosphere was 
maintained by purging with nitrogen at 50 mL/min. Data analysis was completed using 
Universal Analysis 2000 (Version 4.3A) software that was provided by TA Instruments.
 Thermogravimetric analysis (TGA)—TGA was also performed using a Q50 TGA 
from TA Instruments. Samples weighing 5 mg ± 0.5 mg were loaded on a platinum sample 
pan and heated from 25 °C to 350 °C at a rate of 10 °C/min under dry nitrogen at a flow rate 
of 40 mL/min. Data analysis was completed using Universal Analysis 2000 (Version 4.3A) 
software that was provided by TA Instruments.
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 Evaluation of aerosol performance of vancomycin
 Aerosizer LD—The aerodynamic diameter and size distributions of the dry powder were 
determined by time-of-flight measurement (TOF) using an Aerosizer LD (Amherst 
Instruments, Hadely, MA) equipped with a 700 μm aperture operating at 6 psi. 
Approximately 1 mg of the powder was added to the instrument disperser and data was 
collected for ~60 s under high shear (~3.4 kPa). The instrument size limits were 0.10–200 
μm and particle counts were above 100,000 for all measurements.
 Fast Screening Impaction (FSI)—Vancomycin dispersion performance was 
investigated using a Fast Screening Impactor (FSI; MSP Corporation, Shoreview, MN) at a 
flow rate of 90 L/min for 2.6 s (4 L inhalation volume). Capsules (HPMC type, size 3, 
generously provided from Capsugel®, NJ, USA) containing 30 mg ± 0.5 mg of vancomycin 
powder was inserted into a Plastiape Monodose Inhaler® RS01 Model 7, the capsules 
punctured, and the powder was drawn through the FSI. The cut-off aerodynamic diameter 
for the pre-separator was 5 μm. After actuation, the capsule and device along with 
components of the FSI were washed with predetermined volumes of phosphate buffer pH 
3.2. Appropriate sample dilutions were done prior to testing by UV–Vis spectrophotometer 
(Agilent, Santa Clara, CA) at 280 nm. All FSI tests were carried out under controlled 
conditions (21 ± 2 °C, 50 ± 5% relative humidity (RH)) in triplicate.
 Andersen Cascade Impaction (ACI)—Aerodynamic characteristics of vancomycin 
dry powder were analyzed using an eight-stage Mark II Andersen Cascade Impactor (Tisch 
Environmental, Inc.) with or without an endotracheal tube (see below). ACI experiments 
were operated at 90 L/min for 2.6 s (4 L inhalation volume). All ACI experiments were 
performed under controlled conditions (21 ± 2 °C, 50 ± 5% RH) in triplicate. The emitted 
dose (ED), the emitted fraction, and the delivery efficiency were determined. Delivery 
efficiency is the fine particle fraction of the total dose (FPFTD < 5 μm). The fine particle 
fraction of the emitted dose (FPFED) was determined from the cumulative mass distribution 
curve at 5 μm and 3 μm and was calculated as a function of the emitted dose. Additionally, 
mass median aerodynamic diameter (MMAD) and geometric standard deviation (GSD) were 
determined from the cumulative mass distribution curve.
 a) ACI using a Monodose Inhaler®—The powder was delivered into the cascade 
impactor with a standard bent throat or a custom fabricated straight throat (to mimic dorsal 
recumbency of the intubated rabbits) by placing capsules (HPMC type, size 3, generously 
provided from Capsugel®, NJ, USA) containing 30 mg ± 0.5 mg of powder into the 
Monodose® Inhaler. The capsule was punctured and the powder was drawn through the 
cascade impactor. After actuation, the device, capsule, adapter with the endotracheal tube, 
throat (or straight throat), all plates, stages and the glass filter were individually extracted 
into separate volumetric flasks using phosphate buffer pH 3.2. Proper sample dilutions were 
made before quantifying by UV–Vis spectrophotometer.
 b) ACI using a custom throat intubated with an endotracheal tube—Prior to in 
vivo work, in vitro ACI experiments were conducted to evaluate initial aerosol particle sizes 
and deposition following the drug delivery through an endotracheal tube. Briefly a modified 
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insufflator (Supplementary Fig. 1&2) was fabricated to accommodate: 1) a larger drug 
powder reservoir (standard insufflator reservoir holds ~5mg of vancomycin dry powder), and 
2) a catheter that could be introduced through a pediatric endotracheal tube. Both the 
endotracheal tube with its enclosed catheter tube was inserted into the straight throat with 
each tip slightly protruding into the O-ring inlet cone (Fig. 1 & Supplementary Fig. 3) to 
bypass the throat mimicking in vivo dorsal recumbency intubation. Insufflation was actuated 
at the beginning of the inhalation cycle. After drug delivery, the drug reservoir, adapter along 
with the endotracheal and catheter tubes, straight throat, all plates, stages and the glass filter 
were individually extracted using phosphate buffer pH 3.2 and properly diluted before 
quantifying by UV–Vis spectrophotometer.
 Evaluation of the delivery efficiency of the modified insufflator compared to 
the standard insufflator—Preliminary studies were carried out before in vivo 
experiments to test the delivery efficiency of the modified insufflator. The standard 
insufflator (ISF) or the reservoir attached to the modified insufflator (M-ISF) was loaded 
with 5–30 mg dry powder vancomycin. The powder was ejected from each device with 5 mL 
of air via a syringe and was collected into a sealed plastic bag. The amount of vancomycin 
powder collected in the bag was determined gravimetrically and the Emitted Fraction (%EF) 
was calculated; expressed at the amount of powder collected as a fraction of the initial 
delivery mass.
 Pulmonary delivery and pharmacokinetic characterization of vancomycin dry powder in 
intubated rabbits
Female New Zealand White rabbits (2.6–3.5 kg) were purchased from Charles River. Prior 
to anesthesia induction, rabbits were given a pre-analgesic mix of buprenorphine (0.3 
mg/kg) and acepromazine (10 mg/kg) subcutaneously. Thirty minutes later, anesthesia was 
induced by intramuscular administration of ketamine (40 mg/kg) and xylazine (5 mg/kg). 
Rabbits were placed under inhaled isoflurane anesthesia (0.5%–2%) for maintenance 
anesthesia for surgical procedures. An indwelling catheter (22 gauge) was placed in the 
marginal ear vein and flushed with 0.25 mL 100 U/mL heparin in sterile saline. The 
indwelling catheter was then glued with tissue glue (Dermabond®) and sutured to the ear for 
stabilization. Elizabethan collars were placed to prevent animal-induced catheter removal. 
Rabbits receiving intravenous (i.v.) vancomycin were given a bolus dose of vancomycin (1 
mg/kg) in 1 ml/kg sterile saline and the catheter flushed with an additional 0.1 mL 100 
U/mL heparin in sterile saline. Rabbits receiving inhaled dry powder vanocomycin (1 or 5 
mg/kg) were intubated with a pediatric endotracheal tube (2.5 mm I.D. X 3.7 mm O.D. X 
155 mm length, Smiths Medical, Dublin, OH). Vancomycin powder was delivered through 
an endotracheal catheter attached to a modified insufflator (see Figure 1 and Supplemental 
Figures 1–2, Penn-Century, Wyndmoor, PA). Prior to dry powder delivery, the animal was 
momentarily unhooked from the isoflurane anesthesia. The catheter of the modified 
insufflator (0.6 mm I.D. X 1.2 mm O.D. X 153 mm length) was inserted fully into the 
endotracheal tube and the powder was delivered during animal inhalation (inhalation was 
determined with a stethoscope) via 5 mL of air pushed through the insufflator syringe; the 
modified insufflator and endotracheal tube was then removed. To reverse the anesthesia 
following drug delivery, animals were given yohimbine (0.2 mg/kg i.v.) through the marginal 
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ear vein catheter and monitored until recovery (~20–40 minutes post yohimbine 
administration). Blood (0.5 mL) was collected from the marginal ear vein cathether at 0.5, 1, 
2, 4, 6, and 24 hours post vancomycin administration for the isolation of plasma and the 
catheter was kept patent by flushing 0.5 mL 100 U/mL heparin in sterile saline after each 
blood draw. Animals were housed in an AAALAC accredited facility and all experiments 
were approved by the University of Kansas IACUC.
 Plasma Quantification of Vancomycin—Rabbit plasma samples collected were 
analyzed by an LC/MS method as describe previously.28, 29 Breifly, standards of 
vancomycin ranging from 10 ng/mL to 25,000 ng/mL using blank plasma were prepared for 
quantification, and gentamicin was used as an internal standard. A protein precipitation 
extraction method was utilized for both plasma samples and spiked vancomycin standards. 
Briefly, 20 μl of plasma or standards were spiked with 500 ng/ml gentamycin as an internal 
standard and were then were precipitated with a solution of 500 μl of ACN containing 0.25% 
trifluoroacetic (TFA) acid. Samples were vortexed then centrifuged for 5 minutes at 13000 
rpm. The supernatant was collected and then evaporated to dryness at 1 mm Hg and 40°C. 
Samples were reconstituted in 100 μl of water containing 0.25% TFA and vortexed. 10 μL of 
each sample was injected into the LC/MS system, which was comprised of Shimadzu 
LC20AD Pumps, Shimadzu CT020A Column Oven, and Shimadzu CBM20A System 
Controller. A Waters X-Bridge 2.1x50 mm, 3 μm column was used with mobile phase A of 
deionized water and mobile phase B of 95/5/0.1 ACN/deionized water/formic acid with a 
flow rate of 0.3 L/min. Initial conditions were 10% mobile phase B and increased to 95% B 
by 4 minutes; the gradient was performed at 40°C. The MS system used was an AB Sciex 
3200 Linear Ion Trap mass spectrometer that employed ESI positive mode and quantitated 
by Analyst 1.6.1 software (AB SCIEX, Ontario, Canada). Vancomycin-144 was detected 
using Q1 of 725.1 and Q3 of 144.1 with a retention time of 3.75 minutes, while gentamicin 
standards used Q1 of 479.6 and Q3 of 160.3 with a retention time of 2.50 minutes.
 PK analysis—Pharmacokinetic parameters were determined using WinNonLin 
Pharmacokinetic Software, version 3.1 (Pharsight, Mountain View, CA). Non-
compartmental modeling analysis was performed assuming first order input with uniform 
weighing. Extravascular dosing was chosen for the inhaled administration, while vascular 
dosing was chosen for the IV group. Plasma type modeling and linear trapezoid 
interpolation calculation were employed to get the desired PK parameters, which included 
Cmax, Tmax, half-life, AUC, clearance, volume of distribution, and terminal slope.
 Results
 Physicochemical characterization of vancomycin dry powder
The purity of vancomycin B (active component of vancomycin) was 92.03% ± 0.08% and 
any individual impurity for dry powder was less than 4%. The water content was measured 
by Karl Fischer and was equal to 4.8% ± 1.0% for vancomycin dry powder. The potency of 
vancomycin was chemically analyzed and found to be 94.86% ± 0.68%. Scanning electron 
microscopy (SEM) of vancomycin dry powder revealed drug particles of various shape and 
size with an average particle size of ~5 μm (Fig. 2). Bulk and tap densities of micronized 
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vancomycin were determined to be 0.35 ± 0.01 g/cm3 and 0.51 ± 0.01 g/cm3, respectively. 
The surface area of dry powder was determined to be 1.59 m2/g.
The thermal properties of vancomycin powder were investigated by differential scanning 
calorimetry (DSC) and thermogravimetric analysis (TGA). The DSC data exhibited a broad 
endothermic event at 123.7°C and then other two endothermic peaks at 238.2°C and 
288.1°C followed by subsequent degradation of the compound (Fig. 3A). Also, TGA was 
performed on the material and a small step change in TGA was noted at ~50°C, which may 
possibly be due to the loss of water from the compound, followed by a 7% loss at 200°C, 
which could be attributed to the first characteristic endotherm of vancomycin (Fig. 3B). A 
large weight loss of 25% began at 296°C, which may be due to the second characteristic 
endotherm of the drug (Fig. 3C).
The aerodynamic size distribution of the micronized dry powder was determined on a time-
of-flight instrument. The median aerodynamic diameter (MAD) was 2.8 μm with 50% of the 
powder below 2.7 μm and with 95% of the powder below 7.7 μm (Fig. 4). FSI results were 
consistent with the Aerosizer data. The aerosol deposition profiles showed that the majority 
of vancomycin powder was delivered from the device with %EF higher than 90%, with 
minimal (< 10%) powder remaining in the capsule and device (Table 3 & Fig. 5A). Only 
32% was deposited on the filter of the FSI, which corresponds to particles with a diameter 
less than 5 μm (FPF). Delivery efficiency was found to be ~30%.
Aerosizer and FSI results were corroborated by Andersen Cascade Impaction studies at air 
flow rates of ~90 L/min. The dry vancomycin powder was delivered into the cascade 
impactor using the standard USP bent throat and the Monodose® inhaler. A bimodal 
distribution was observed with peaks at 8 μm (Stage -2) and 1.1 μm (stage 3) (Fig 5B). 
These results correspond to the particle size variation that was observed in SEM images. The 
high emitted fraction (~98%) of the dry powder suggested efficient aerosolization of the 
powder out of the device and capsule. However, the anticipated total lung deposition (i.e. 
FPF <5 μm) was only about 26%. In addition, the MMAD was ~7 μm with a high geometric 
standard deviation (GSD) (Table 2).
A straight throat was fabricated to mimic dorsal recumbency of the intubated rabbits 
(Supplemental Figure 3). To validate the efficiency of this throat, the standard USP throat 
was replaced by a custom straight throat and ACI experiments were performed using the 
Mondose® inhaler under the same conditions. There was no significant difference in the 
aerosol performance except with lower EF% (79% vs. 98%) in case of the fabricated throat 
(Table 4 & Fig. 5B).
In vitro ACI experiments were conducted using a modified insufflator to assess the 
deposition efficiency following drug delivery by the new catheter-endotracheal system prior 
to in vivo delivery to rabbits. The insufflator was connected to a drug reservoir and a 
catheter placed into a pediatric-sized endotracheal tube that passed through the straight 
throat to mimic in vivo intubation. To compare the delivery between the modified insufflator 
and the Monodose®, a Mondose® inhaler was attached directly to the endotracheal tube 
(without catheter) and was inserted into the straight throat for ACI evaluation. Powder 
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distribution did not show any significant difference following drug delivery by modified 
insufflator and Mondose® inhaler (Table 2 & Fig. 6). However, substantial powder was 
retained in the Monodose® device, capsule, and endotracheal tube (32% of filling mass), 
while the modified insufflator/catheter system exhibited negligible retained powder in the 
drug reservoir and catheter-endotracheal system (Fig. 6).
To further test the delivery efficiency of the modified insufflator-reservoir system compared 
to the standard insufflator (ISF), 5 mg of vancomycin powder was loaded in both devices 
and ejected with 5 mL of air. There was no significant difference in the %EF after drug 
delivery (Fig. 7). Moreover, loading the reservoir attached to the modified insufflator (M-
ISF) loaded with 5–30 mg dry powder vancomycin showed an increase in the EF from ~80% 
(5 mg initial filling mass) to ~90% (15–30 mg initial filling mass) (Fig. 7).
To evaluate pulmonary delivery as a feasible route of administration for dry powder 
vancomycin, we compared pharmacokinetic profiles of rabbits given intravenous 
vancomycin solution or pulmonary insufflated vancomycin dry powder through an 
endotracheal tube catheter.30 As expected, Tmax in i.v. vancomycin was early (0.67 h), 
whereas plasma vancomycin concentrations in rabbits administered pulmonary vancomycin 
dry powder increased until Tmax was achieved at approximately 2 h, which was independent 
of inhaled dose (Table 3, Fig. 8). Cmax was dose dependent when vancomycin was inhaled as 
it increased 4.3 fold in rabbits receiving 5 mg/kg compared to 1 mg/kg inhaled vancomycin. 
Interestingly, the terminal slope was not different between any group receiving vanomycin. 
Importantly, the AUC in groups receiving 1 mg/kg intravenous or pulmonary vancomycin 
were similar; as expected the AUC was increased in rabbits receiving 5 mg/kg inhaled 
vancomycin. The clearance rate in rabbits receiving 1 mg/kg vancomycin tended to be 
higher in the intravenous group compared to the inhaled group, although this did not achieve 
the level of statistical significance (p=0.054). The data suggest that inhalation of dry powder 
vancomycin may be an efficient method to deliver antibiotics to the lungs of intubated 
patients.
 Discussion
The acceptance criteria for the % vancomycin B (active component of vancomycin) in the 
sample should not be less than 85% and the percent of any peak other than the main peak 
should not be more than 5%, as reported by the USP.22 Here, the purity of the vancomycin 
was within the acceptable range. It is well-known that vancomycin HCl is a highly 
hygroscopic drug that can absorb moisture if not packaged appropriately.31 The potency 
assay showed that the drug content complied with the pharmacopoeial limits for content 
uniformity with standard deviation <2%.
DSC results indicated that the early endothermic peak may be suggestive of the hydrate form 
of the compound. The melting endotherm at 238.2°C may be evidence of the characteristic 
endothermic peak of the anhydrous form of vancomycin. In a similar experiment, the 
material was also heated from 25 to 200°C (the temperature prior to the characteristic peak 
of the drug) with a heating rate of 20°C/min under dry nitrogen at 50 mL/min followed by 
cooling the powder to room temperature using aluminum hermetic pans with holes. Then, 
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the material was re-heated to 350°C at the same rate. This experiment demonstrated the 
disappearance of the first endothermic peak and only the appearance of the two melting 
endotherms at 238.2°C and 288.1°C was observed (Fig. 3B). These data support the 
hypothesis of water loss from the hydrated compound.
The aerodynamic properties of inhaled aerosols are a major contributor to the therapeutic 
administration of pulmonary delivered therapeutics. Typically, particles with a mean mass 
aerodynamic diameter (MMAD) of 1–5 μm are considered fine aerosol particles which can 
deposit in the respiratory airways whereas larger particles tend to deposit in the upper 
conducting airways and in the mouth and throat. It is important to note that P. aeruginosa 
colonizes both the alveolar space and the pulmonary sputum32 suggesting that inhaled 
therapeutics with complete lung coverage (wide particle distribution) may be more 
efficacious than a uniform fine aerosol typically found in nebulized vapors. Using well 
defined Anderson Cascade Impaction tests with a Monodose® inhaler, we found that 
vancomycin dry powder could be aerosolized with a high emitted fraction. Direct inhalation 
of the dry powder into a dry endotracheal tube resulted in approximately 10% of the dose 
being deposited on the side of the endotracheal tube after ACI, which is substantially less 
than what was found in the USP throat after traditional ACI using a Monodose inhaler (22 
± 5 %). Importantly, use of a catheter to deliver the dry powder increased delivery of dry 
powder to the lung without compromising the fine particle fraction. As humidity droplets 
tend to build up in endotracheal tubes (and nebulization circuits), we hypothesize that this 
result underestimates the true benefit of delivering aerosols through a fresh endotracheal 
tube catheter, which would minimize the amount of drug powder stuck to the side of the 
endotracheal tube or circuit allowing for more complete and reproducible delivery of the 
prescribed therapeutic directly into the pulmonary system.21
Unlike current nebulization strategies, our dry powder delivery method is highly efficient at 
delivering aerosols to the lung in a single 5 mL puff of air with high and consistent emitted 
fractions (>85%). The single dosing puff delivery scheme presented here eliminates 
variability accumulated over lengthy nebulization times (10–15 minutes) and ventilator-
dependent duty cycling, albeit the dose administration of our method should be closely 
timed with patient inhalation to facilitate deep lung penetration. Additionally, our novel 
device aerosolizes the dry powder with minimal external air input (5 mL), suggesting that 
this scheme could be integrated into both adult and pediatric ventilator circuits without the 
need to dramatically alter the tidal volume or humidity settings of the ventilator prior to 
dosing. Furthermore, the use of a valved endotracheal tube suction adapter port placed 
directly onto the endotracheal tube, into both traditional humidified ventilator circuits and 
ventilator circuits utilizing heat and moisture exchangers (HMEs) as the primary humidity 
source to enable a more uniform dosing protocol among different ventilator support systems 
and hospitals. Taken together, this effective and standardized approach for delivery of an 
inhaled dry powder antibiotic could dramatically improve the standard of care in ventilated 
patients suffering from antibiotic pneumonia.
To test this concept, we developed a new device and pulmonary drug delivery method for 
administration of vancomycin dry powder to intubated rabbits. Utilizing this novel drug 
delivery system, we compared the pharmacokinetic profile of intravenously administered 
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vancomycin solution and inhaled vancomycin dry powder. Exposures of vancomycin were 
similar in rabbits receiving 1 mg/kg vancomycin via intravenous solution compared to dry 
powder insufflation through an endotracheal tube catheter, suggesting that a majority of the 
pulmonary delivered dry powder was absorbed from the lungs into systemic circulation, 
although we cannot exclude that some powder deposited in the upper airways may have been 
cleared via mucociliary clearance mechanisms. Direct delivery into the lungs did not alter 
the pharmacokinetic half-life or terminal slope of vancomycin, suggesting minimal if any 
biotransformation of the dry powder in the lung; however, the clearance rate tended to 
decrease in rabbits receiving 1 mg/kg pulmonary delivered vancomycin and was probably 
due to the initial ~2 h absorption phase. Importantly, this resulted in reduced peak plasma 
concentrations (Cmax) of vancomycin when compared to rabbits given an equivalent bolus 
intravenous dose. Furthermore, as the active drug is delivered straight into the lung, higher 
local concentrations can be achieved, while simultaneously reducing systemic exposure and 
mitigating the risk of kidney toxicity. Taken together, this study suggests that inhaled 
vancomycin dry powder may be a convenient and safe dosing route for patients with 
pneumonia.
 Conclusion
We have characterized both the physical and aerodynamic properties of vancomycin as a 
pharmaceutical dry powder aerosol. We also designed a novel method of direct pulmonary 
delivery to rabbits by using a catheter system that minimizes drug deposition in the 
endotracheal tube. This deliver system completely bypasses ventilator circuit tubing, 
allowing increased delivery efficiency of the aerosol without the need for substantial 
ventilator adjustment. Using this new dosing method, we found that dry powder vancomycin 
can be efficiently delivered to the lungs of intubated rabbits through pediatric-sized 
endotracheal tubes. This rapid delivery method may serve as a reproducible alternative to 
intravenous infusion or nebulization of vancomycin solution to ventilated patients. 
Furthermore, this device may serve as a model to improve local delivery of other dry powder 
pulmonary therapeutics such as bronchodilators, surfactants, or anti-cancer agents to 
ventilated patients.
 Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Schematic of the new insufflator- catheter system passing through an endotracheal tube.
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Scanning electron micrographs of vancomycin dry powder.
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A) Differential Scanning Calorimetry (DSC) thermogram for vancomycin dry powder; 
vancomycin dry powder was heating to 20°C (red line), then cooled to room temperature 
followed by subsequent reheating to 350°C (blue line) compared to the direct heating of the 
powder to 350°C (black line). B) Thermogravimetric analysis (TGA) for vancomycin dry 
powder.
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Aerodynamic size distributions of vancomycin dry powder determined by time-of-flight 
analysis.
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A) FSI deposition profile of vancomycin dry powder at a flow rate of 90 L/min for 2.7 s 
using Monodose® inhaler (model 7 standard) with the standard USP throat. B) ACI 
deposition profile of vancomycin dry powder at a flow rate of 90 L/min for 2.67 s using a 
Monodose® inhaler (model 7 standard) with a standard USP throat (black bars) or a 
modified straight throat (gray bars) without an endotracheal tube.
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The ACI deposition profile of vancomycin dry powder at a flow rate of 90 L/min for 2.67 s 
using; A) Monodose inhaler (model 7 standard) attached to an endotracheal tube; B) 
Modified insufflator attached to a catheter passing through endotracheal tube.
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(A) The percentage of powder collected following the delivery of 5 mg loaded vancomycin 
powder by the modified insufflator (M-ISF, gray) compared to the standard insufflator (ISF, 
black) using 5 mL of air for. (B) The percentage of powder collected following the delivery 
of various loaded doses of vancomycin powder by modified insufflator using 5 mL of air.
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Pharmacokinetic parameters of vancomycin dry powder following i.v. and pulmonary drug 
administration (values = average ± S.D., n = 3).
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Table 1
FSI results of the vancomycin dry powder at 90 L/min. (n=3; ± S.D.).
Characteristics of the dry powder Vancomycin dry powder
FPFa (<5 μm) as % 32 ± 10
FPDb (<5 μm, mg) 10 ± 2
Delivery efficiency (<5 μm) 30 ± 5
EFc (%) 94 ± 6
EDd (mg) 30 ± 3
a
FPF: Fine Particle Fraction
b
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Table 3
Pharmacokinetic parameters of vancomycin dry powder following i.v. and pulmonary drug administration 
(values = average ± S.D., n = 3).
PK parameters
Subject
1 mg/kg I.V. 1 mg/kg Inhaled 5 mg/kg Inhaled
Terminal Slope (1/hr) 0.2073 ± 0.0282 0.2244 ± 0.0272 0.2369 ± 0.0208
Half-Life (hr) 3.38 ± 0.43 3.12 ± 0.40 2.94 ± 0.25
Tmax (hr) 0.67 ± 0.29 2.00 ± 0.00 2.67 ± 1.15
Cmax (ng/mL) 3330 ± 1119 1697 ± 337 6917 ± 724
C0 (ng/mL) 5347 ± 4927 N/A N/A
AUClast (hr*ng/mL) 12069.85 ± 638.15 16066.85 ± 2877.14 67100.93 ± 4552.18
AUC(0-∞) (hr*ng/mL) 12135.34 ± 616.52 16135.36 ± 2840.68 67304.80 ± 4482.83
Volume of Dist. (mL/kg) 403.89 ± 64.83 289.64 ± 91.54 316.87 ± 42.58
Clearance (mL/hr/kg) 82.55 ± 4.25 63.33 ± 11.60 74.50 ± 4.93
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